Mimedx Group Inc Stock Price, News & Analysis

MiMedx Group, Inc. (MDXG) reports Q2 2021 net sales of $68.2 million, a 27% increase from Q2 2020's $53.6 million. Adjusted net sales reached $67.9 million, up 30.6%. The net loss decreased to $1.8 million from $8.5 million in the prior year. Gross profit margin declined to 81.3% due to higher expenses, including a 43.6% rise in selling, general, and administrative costs. The company is on track to release topline results for its musculoskeletal pipeline by late summer and anticipates steady adjusted net sales for 2021.

Marietta, Ga., July 20, 2021 - MiMedx Group, Inc. (Nasdaq: MDXG) will report its financial results for Q2 2021 on August 3, 2021, after market close. The company specializes in regenerative medicine using amniotic tissue and has a pipeline aimed at musculoskeletal conditions. A conference call will be held on August 4, 2021, at 8:30 am ET to discuss the results. MiMedx boasts a portfolio of over two million allografts supplied, highlighting its stronghold in the healthcare sector.

MIMEDX Group, Inc. (Nasdaq: MDXG) congratulates Dr. Cato T. Laurencin on receiving the NAACP's Spingarn Medal, recognizing his pioneering work in regenerative medicine and biomaterials science. Dr. Laurencin, a member of the MIMEDX Board, is honored for his contributions to tissue regeneration and innovation. He is the first surgeon elected to four national academies and has more than 500 publications. Timothy R. Wright, MIMEDX CEO, praises Dr. Laurencin's impact on advancing human health through science.

Marietta, GA-based MiMedx Group, Inc. (Nasdaq: MDXG) announced its inclusion in the Russell 3000® and 2000® indexes as of June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community, according to CEO Timothy R. Wright. The addition underscores MiMedx's recovery and strategic execution since relisting on Nasdaq in November 2020. Approximately $10.6 trillion in assets are benchmarked against Russell's indexes, which are favored by investment managers and institutional investors for their indexing strategies.

Marianna, Ga. - MiMedx Group, with the stock symbol MDXG, has announced its participation in the Raymond James 2021 Human Health Innovation Conference on June 23, 2021, at 11:20 AM ET. The presentation will feature CEO Timothy R. Wright, CFO Peter M. Carlson, and EVP Robert B. Stein, M.D., Ph.D. Interested parties can access the live webcast via the company’s website or through the conference link. MiMedx specializes in regenerative medicine using amniotic tissue and has shipped over two million allografts, focusing on treating chronic wounds and degenerative conditions.

MiMedx Group has published a peer-reviewed study in the Journal of Investigative Dermatology, focusing on its Purion processed dehydrated human amnion/chorion membrane (dHACM). The research investigates the potential of dHACM to combat excessive fibrosis, affecting over 100 million people globally. Findings indicate that dHACM disrupts the TGF-β1 signaling pathway, regulating fibrotic activity and reducing pathological scar formation. MiMedx's CEO emphasized the continuous R&D investments to enhance understanding and application of their amniotic tissue technologies.

MIMEDX Group, Inc. (Nasdaq: MDXG) has received regulatory approval from the Japanese Ministry of Health for its EPIFIX allograft, allowing it to market this product in Japan. EPIFIX is designed to aid the healing of chronic wounds like diabetic foot ulcers and venous leg ulcers. The approval is projected to benefit up to 100,000 new patients annually. MIMEDX is now focusing on establishing reimbursement and distribution networks, aiming for EPIFIX availability in early 2022.

MIMEDX Group, an industry leader in regenerative medicine using amniotic tissue, announced that key executives will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

Date: June 4, 2021
Time: 2:00 PM ET
Webcast Link: Join Here

MIMEDX specializes in developing placental tissue allografts for healthcare sectors, processing tissues through proprietary methods and maintaining high production standards.

MIMEDX Group, Inc. (NASDAQ: MDXG) has extended the deadline for shareholders to pre-register for the 2021 Annual Meeting to May 26, 2021, at 10:00 a.m. Eastern Time. The virtual meeting is scheduled for May 27, 2021, at 10:00 a.m. Eastern. Shareholders are advised to pre-register to participate. Details on pre-registration can be found in the Company's definitive proxy statement or online at www.votemimedx.com. Shareholders eligible to vote must be on record as of April 16, 2021.